Figure 4 | Scientific Reports

Figure 4

From: The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

Figure 4

Reduced SR calcium content and cytosolic calcium removal in sorafenib treated cardiomyocytes. Sorafenib (10 µM) reduces SR calcium content as assessed by rapid caffeine (30 mM) application (a), and reduces the rate constant of cytosolic calcium removal through SERCA (1/TauSR) (b). n = 3–10 cells/3–5 hearts. *p < 0.05 and #p < 0.01 vs. control by t-test.

Back to article page